Equaline Extra Strength Assorted Berry Antacid Tablet, Chewable
FDA Recall NDC 41163-129

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Equaline Extra Strength Assorted Berry Antacid (NDC 41163-129). A significant event, classified as Class II, was initiated on May 28, 2026 by United Natural Foods, Inc. Dba Unfi. The reported reason for this action was: "Presence of foreign substance: small metallic particles in chewable tablets."

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

May 2026 Class II Recall: Presence of foreign substance

Recall Number
Class II Ongoing
Reason for Recall
Presence of foreign substance: small metallic particles in chewable tablets.
Initiated
May 28, 2026
Reported
Jun 10, 2026
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
99098
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Guardian Drug Co. Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
U.S.A. Nationwide
Product Description
EQUALINE extra strength, antacid tablets, calcium carbonate 750mg, 96 chewable tablets, DISTRIBUTED BY SUPERVALU INC.,EDEN PRARIE, MN 55344 USA, NDC 41163-129-22.
Batch or Lot Expiration Information
Lot# : 1276118, expires: JAN- 2029.
Affected Packages Involved in this Recall
41163-129-66Product
41163-129-22Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.